Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Dec;96(6):2966-74.
doi: 10.1172/JCI118368.

Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate

Affiliations

Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate

C P Genain et al. J Clin Invest. 1995 Dec.

Abstract

In the human disease multiple sclerosis (MS), the immune mechanisms responsible for selective destruction of central nervous system myelin are unknown. In the common marmoset Callithrix jacchus, a unique demyelinating form of experimental allergic encephalomyelitis resembling MS can be induced by immunization with whole myelin. Here we show that the MS-like lesion can be reproduced by immunization against the extracellular domain of a single myelin protein, myelin/oligodendrocyte glycoprotein (MOG). By contrast, immunization against the quantitatively major myelin proteins myelin basic protein or proteolipid protein results in inflammation but little or no demyelination. Furthermore, in the presence of encephalitogenic (e.g., disease-inducing) T cells, the fully demyelinated lesion is reconstructed by systemic administration of IgG purified from whole myelin-, or MOG-immunized animals, and equally by a monoclonal antibody against MOG, but not by control IgG. Encephalitogenic T cells may contribute to the MS-like lesion through disruption of the blood-brain barrier that permits access of demyelinating antibody into the nervous system. The identification of MOG as a major target antigen for autoimmune demyelination in a nonhuman primate should facilitate development of specific immunotherapies for human MS.

PubMed Disclaimer

References

    1. J Neurochem. 1989 Jan;52(1):296-304 - PubMed
    1. Lab Invest. 1984 Oct;51(4):416-24 - PubMed
    1. Am J Pathol. 1993 Aug;143(2):555-64 - PubMed
    1. Nat Med. 1995 Mar;1(3):244-8 - PubMed
    1. J Immunol. 1987 Dec 15;139(12):4016-21 - PubMed

Publication types

MeSH terms